使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day, and thank you for standing by. Welcome to the Twist Bioscience fiscal 2026 fourth quarter financial results conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
大家好,感謝您耐心等候。歡迎參加 Twist Bioscience 2026 會計年度第四季財務業績電話會議。(接線員指示) 請注意,今天的會議將被錄音。
I would now like to hand the conference over to your first speaker today, Angela Bitting, SVP of Corporate Affairs. Please go ahead.
現在我想把會議交給今天的第一位講者,企業事務資深副總裁 Angela Bitting。請開始。
Angela Bitting - Senior vice president, Corporate Affairs
Angela Bitting - Senior vice president, Corporate Affairs
Thank you, operator. Good morning, everyone, and thank you for joining us to review Twist Biosciences fiscal 2026 fourth quarter and full year results and business progress. Our earnings release is available at www.twistbioscience.com. With me today are Dr. Emily Leproust, CEO and Co-Founder; Dr. Patrick Finn, President and COO; and Adam Laponis, CFO. We will discuss our business progress, financial and operational performance and growth opportunities, followed by questions. As a courtesy to others, please limit yourself to one question and then requeue. This call is being recorded. The audio will be archived in the Investor Relations section of our website and available for two weeks.
謝謝,接線員。各位早安,感謝各位加入我們,一同回顧 Twist Biosciences 2026 會計年度第四季及全年業績與業務進展。我們的財報新聞稿已發布於 www.twistbioscience.com。今天與我一同出席的有:共同創辦人暨執行長 Emily Leproust 博士;總裁暨營運長 Patrick Finn 博士;以及財務長 Adam Laponis。我們將討論業務進展、財務與營運表現及成長機會,之後進行問答。為了體諒其他與會者,請每位提問者僅提一個問題,之後再重新排隊。本次電話會議將被錄音。音訊將存檔於我們網站的投資人關係專區,並提供兩週供收聽。
During today's presentation, we will make forward-looking statements within the meaning of the US federal securities laws. These statements generally relate to future events or future financial or operating performance. Our expectations and beliefs regarding these matters may not materialize, and actual results are subject to risks and uncertainties that could cause them to differ materially from those projected. These risks include those set forth in the press release issued earlier today and those more fully described in our filings with the Securities and Exchange Commission.
在今天的簡報中,我們將在美國聯邦證券法的意義下作出前瞻性陳述。這些陳述通常涉及未來事件或未來的財務或營運表現。我們對於這些事項的預期與信念可能無法實現,實際結果亦可能受到風險與不確定性影響,而與預測內容出現重大差異。這些風險包括今日稍早發布之新聞稿所列風險,以及我們向美國證券交易委員會提交文件中更完整描述的風險。
Our forward-looking statements are based on information available to us today, and we disclaim any obligation to update them except as required by law. We will also discuss adjusted EBITDA, a financial measure that does not conform with generally accepted accounting principles. This measure may be calculated differently from similarly titled measures used by other companies. A reconciliation of historical GAAP and non-GAAP financial measures and information about our forward-looking non-GAAP guidance are included in our earnings materials available in the Investor Relations section of our website.
我們的前瞻性陳述係基於截至今日我們可取得的資訊,除法律要求外,我們不承擔更新該等陳述之義務。我們也將討論調整後 EBITDA,此為不符合一般公認會計原則(GAAP)的財務衡量指標。此指標的計算方式可能與其他公司使用的同名指標不同。歷史 GAAP 與非 GAAP 財務衡量指標的調節表,以及我們前瞻性非 GAAP 指引的相關資訊,均包含於我們的財報資料中,可於網站投資人關係專區取得。
With that, I will turn the call over to Emily.
接下來,我把電話會議交給 Emily。
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
Thank you, Angela, and good morning, everyone. Fiscal 2026 was a pivotal year for Twist. We accelerated top line revenue growth delivered positive adjusted EBITDA in the fourth quarter and expanded our capabilities for the opportunities ahead. On slide 3, we reported that fourth quarter revenue was $126.6 million, up 28% year-over-year. This is our 15th consecutive quarter of sequential growth.
謝謝你,Angela,各位早安。2026 會計年度對 Twist 而言是關鍵的一年。我們加速營收成長,在第四季實現調整後 EBITDA 轉正,並擴充能力以把握未來機會。在第 3 張投影片中,我們報告第四季營收為 1.266 億美元,年增 28%。這是我們連續第 15 個季度實現逐季成長。
On slide 4, full year revenue reached almost $460 million, up 22% and more than $30 million above our initial 2026 guidance. Over the last three years, revenue grew at a compound annual rate of 23% with NGS aplications growing 24% and DSPs growing 22%. Full year gross margin reached 52.4%. Fourth quarter adjusted EBITDA was positive at $2.2 million, delivering the milestone we committed to several years ago. These results demonstrate the strength of our platform and the discipline of our team. It took years of work to build and iterate the manufacturing infrastructure we have today. And as we scale our infrastructure, we have Oslo expanded our commercial reach and now serve thousands of customers routinely.
在第 4 張投影片中,全年營收接近 4.60 億美元,年增 22%,並較我們最初的 2026 年指引高出逾 3,000 萬美元。過去三年,營收以 23% 的複合年成長率成長,其中 NGS 應用成長 24%,DSP 成長 22%。全年毛利率達 52.4%。第四季調整後 EBITDA 為正,達 220 萬美元,實現我們數年前承諾的里程碑。這些成果展現了我們平台的實力與團隊的紀律。我們花了多年時間打造並反覆優化如今的製造基礎設施。隨著我們擴大基礎設施規模,我們也擴展了商業觸及範圍,現在可例行性地服務數千名客戶。
Thank you to every Twister who brought us here. Crossing adjusted EBITDA breakeven provides us with more options for how we run Twist. We intend to reinvest our profits in the capabilities, capacity and people that can drive top line growth moving forward.
感謝每一位 Twister 讓我們走到今天。跨越調整後 EBITDA 損益兩平,讓我們在經營 Twist 的方式上擁有更多選擇。我們打算將利潤再投資於能力、產能與人才,以推動未來的營收成長。
On slide 5, for those new to Twist, we write DNA on silicon. By miniaturizing the chemistry by 99.8%, we manufacture 1 million unique sequences in parallel using a very small fraction of the materials required by traditional methods. We believe our proprietary platform gives us a structural advantage in cost, scale and speed. This enables us to provide customization and scale for our customers.
在第 5 張投影片中,對於初次認識 Twist 的朋友,我們是在矽晶片上合成 DNA。透過將化學反應微型化 99.8%,我們能以傳統方法所需材料的一小部分,同步平行製造 100 萬條獨特序列。我們相信自有的專有平台在成本、規模與速度上具備結構性優勢。這使我們能為客戶提供客製化與規模化的服務。
And as health care becomes more personalized, we believe the need for custom manufacturing at scale grows exponentially. Twist was built for that future. Our new product introduction or NPI engine drives volume onto the tip each launch builds on our manufacturing infrastructure, expertise and commercial reach, allowing us to serve more of our customers' workflows and enter new applications.
隨著醫療照護日益個人化,我們相信對於可規模化的客製化製造需求將呈指數型成長。Twist 正是為那樣的未來而打造。我們的新產品導入(NPI)引擎推動每次上市的量能上線;每一次推出都建立在我們的製造基礎設施、專業能力與商業觸及之上,使我們能涵蓋客戶工作流程的更多環節,並進入新的應用領域。
Over the course of the last several years, through the introduction of new products, our first addressable market has expanded from $2 billion to $7 billion with line of sight to $13 billion by 2030. Today, our solutions help customers discover medicines, develop diagnostic tests and advanced research across industries. Each new capability expands what customers can do with Twist. AI-enabled drug discovery is a powerful example of our NPI engine network.
在過去幾年中,透過推出新產品,我們的初始可服務市場已從 20 億美元擴大至 70 億美元,並可望在 2030 年前清楚看到達到 130 億美元的路徑。目前,我們的解決方案協助客戶進行藥物發現、開發診斷檢測,以及跨產業的先進研究。每一項新能力都擴大了客戶可透過 Twist 完成的工作範圍。AI 驅動的藥物發現就是我們 NPI 引擎網路的一個強力例證。
Turning to slide 6. As customers use AI to design more molecules to explore more targets the amount of experimental work they can pursue expands. Those designs need to become physical molecules, the molecules need to be tested, and the results need to be consistent and useful enough to continuously improve model performance. Twist brings those steps together. We manufacture the DNA express the proteins and then test those proteins to generate characterization data.
接著看第 6 張投影片。當客戶使用 AI 設計更多分子、探索更多標的時,他們可進行的實驗工作量也隨之擴大。這些設計需要轉化為實體分子,分子需要被測試,而結果必須足夠一致且具可用性,才能持續提升模型表現。Twist 將這些步驟串聯起來。我們製造 DNA、表達蛋白質,並進一步測試這些蛋白質以產生特性分析資料。
Our role becomes more valuable as the numbers of sequences grow and the experiments become more demanding. Because every customer is different, there are many paths they can choose when pursuing AI-enabled drug discovery, and we build Twist to create value across each of them. Customers can buy individual genes or pool DNA and the exploratory work themselves. They can buy protein and run their own assays or they can use our full workflow from DNA centesis through protein expression and characterization. All of these roads lead to Twist.
隨著序列數量增加、實驗要求更高,我們的角色也變得更有價值。由於每位客戶都不同,在推進 AI 驅動藥物發現時可選擇的路徑很多,而我們打造 Twist 的目標是在每一條路徑上都能創造價值。客戶可以購買單一基因或 DNA 混合池,自行進行探索性工作。他們可以購買蛋白質並自行進行分析測試(assays),或使用我們從 DNA 合成到蛋白表達與特性分析的完整工作流程。所有這些道路最終都通往 Twist。
There are multiple ways to access our platform, each creating a revenue opportunity for Twist. We do not need every customers to follow the same path. Every path offers quality, speed and scale. As AI expands what customers can design, we give them the means to build and test it. Our leadership in this market is built on the ability to execute that work at scale.
客戶可透過多種方式使用我們的平台,而每一種方式都能為 Twist 創造營收機會。我們不需要每位客戶都走相同的路徑。每一條路徑都提供品質、速度與規模。當 AI 擴大客戶可設計的範圍時,我們提供他們建構並測試的手段。我們在此市場的領導地位,建立在能以規模化方式執行這些工作的能力之上。
It is grounded in the manufacturing platform we have spent more than a decade building and in the capabilities we continue to add on top of our strengths. In fiscal 2026 we expanded automation across the business with a particular focus on protein expression and characterization. We introduced complex sets, enabling us to accept the vast majority of sequences up to 7 kilobases. We licensed the B body bispecific technology, a robust platform conducive to our high throughput automation capabilities. And in late October, we launched Twist extra screening antibodies, a self-free offering that delivers proteins in as few as 5 days and characterization data in as few as 8 business days.
這一切奠基於我們花了十多年打造的製造平台,以及我們持續在既有優勢之上新增的能力。在 2026 會計年度,我們在全公司擴大自動化,特別聚焦於蛋白表達與特性分析。我們導入複雜組裝(complex sets),使我們能接受絕大多數長度達 7 kb 的序列。我們取得 B body 雙特異性技術的授權,這是一個穩健的平台,適合我們的高通量自動化能力。並且在 10 月下旬,我們推出 Twist extra screening antibodies,這是一項免細胞(cell-free)產品,可在最短 5 天交付蛋白質,並在最短 8 個工作天提供特性分析資料。
AI drug discovery delivered an exceptional year. Orders more than doubled and revenue grew 175% from $21.5 million in fiscal 2025 to $59.1 million in fiscal 2026. Existing customers return for repeat design-build test learn cycles and new customer trust Twist as their build and test partner. Our reported AI drug discovery revenues for both years reflect the customer we could clearly identify through their orders or set it focus on AI drug discovery.
AI 藥物發現交出非凡的一年。訂單數量超過翻倍,營收自 2025 會計年度的 2,150 萬美元成長 175% 至 2026 會計年度的 5,910 萬美元。既有客戶回流進行重複的「設計-建構-測試-學習」循環,新客戶也信任 Twist 作為其建構與測試合作夥伴。我們兩個年度所揭露的 AI 藥物發現營收,係反映我們能透過其訂單清楚辨識的客戶,或其明確將重點聚焦於 AI 藥物發現的客戶。
Over the last 18 months, we have seen a pattern emerge across successive customer cohorts. Customers start with the pilot order, typically from $10,000 to $100,000. They then place model building orders, often multiple millions of dollars properly for capitalization data. After digesting the data over a quarter or more customers return to conduct actual drug discovery, providing novel targets and sequences for us to build and test. These recurring discovery orders typically run from $250,000 to $1 million in iterative cycles until they have the antibodies that are ready to advance preclinical development.
在過去 18 個月,我們看到在連續的客戶群組之間浮現出一種模式。客戶通常先從試點訂單開始,金額多在 1 萬至 10 萬美元之間。接著他們會下達模型建置訂單,金額往往達數百萬美元,主要用於可資本化的資料。在消化資料一季或更久之後,客戶會回來進行實際的藥物發現,提供新穎的標的與序列,讓我們進行建構與測試。這些反覆出現的發現訂單通常以 25 萬至 100 萬美元的迭代循環進行,直到他們取得可推進至臨床前開發的抗體。
Then they start the process of discovery again with a different target. In general, the run rate revenue for a given customer exceeds model building revenue. And across the business, we believe we will see significant growth in both model building and discovery for many years to come. From the conversations with customers and potential customers, we believe AI will continue to enhance hpw drugs are discovered. Based on the same kind of patients, customers believe they win in more DNA, and more data to support AI drug discovery, and we believe we are still early in this opportunity.
之後,他們會以不同的標的再次啟動發現流程。一般而言,單一客戶的經常性營收(run rate)會高於模型建置營收。而就整體業務而言,我們相信未來多年模型建置與發現兩者都將出現顯著成長。從與客戶及潛在客戶的對話中,我們相信 AI 將持續強化藥物被發現的方式。基於同樣的趨勢,客戶認為更多 DNA 與更多資料將有助於 AI 藥物發現取得勝利,而我們也相信這個機會仍處於早期階段。
Our customers' funnel continues to grow. The revenue opportunity remains robust, and we expect AI drug discovery to remain one of our fastest-growing product groups in fiscal 2027 with orders momentum accelerating throughout the year. We are seeing the durability of the customer base with several cohorts of customers returning in a similar pattern. Our focus today is to ensure we have the capacity for the demand we expect is coming.
我們的客戶漏斗持續擴大。營收機會依然強勁,我們預期在 2027 會計年度,AI 藥物發現仍將是我們成長最快的產品群之一,且訂單動能將在全年加速。我們看到客戶基礎的持久性,數個客戶群組以相似模式回流。我們目前的重點是確保具備足以因應預期需求的產能。
Over the last 12 months, we increased protein and antibody manufacturing capacity by almost 200% and expanded characterization capabilities by 2 times to 5 times, depending on the assay. Moving forward, we are significantly expanding capacity across our DNA, protein and characterization workflows to support larger customer programs and capture growing demand.
在過去 12 個月,我們將蛋白質與抗體製造產能提升近 200%,並依不同檢測(assay)將表徵(characterization)能力擴增 2 倍至 5 倍。展望未來,我們將在 DNA、蛋白質與表徵工作流程上大幅擴充產能,以支援更大型的客戶專案並掌握成長中的需求。
These investments could beyond adding equipment. We are automating the automation, increasing throughput and improving turnaround times across the full workflow. We're also adding another characterization lab in our existing Oregon facility as we continue to expand capacity to stay ahead of customer demand. For many of our characterization assets, this means another 5 times capacity expansion versus where we exited fiscal 2026 giving us the ability to grow with existing customers, serve new customers and convert demand into revenue.
這些投資不僅僅是新增設備。我們正在讓自動化更自動化,提高產出並改善整體工作流程的周轉時間。隨著我們持續擴充產能以領先客戶需求,我們也將在既有的俄勒岡州廠區新增另一間表徵實驗室。對於我們許多表徵資產而言,這代表相較於 2026 會計年度結束時的水準,將再擴增 5 倍產能,使我們能與既有客戶共同成長、服務新客戶,並將需求轉化為營收。
Turning to slide 7. Nucleic acid therapeutics exemplified another large opportunity to expand our platform. These therapies use DNA or RNA to achieve a therapeutic effect. Researcher working on mRNA antisense oligonucleotides and small interfering RNA need to make and evaluate hundreds of thousands to millions of unique sequences. That plays directly to our strength of customization at scale.
接著看第 7 張投影片。核酸治療(nucleic acid therapeutics)展現了另一個擴展我們平台的重大機會。這些療法使用 DNA 或 RNA 來達成治療效果。從事 mRNA、反義寡核苷酸(antisense oligonucleotides)與小干擾 RNA(siRNA)研究的研究人員,需要製作並評估數十萬到數百萬條獨特序列。這正好直接對應到我們「大規模客製化」的核心優勢。
Personalized cancer therapy illustrates the potential in one approach and development, researcher identify mutations in a patient's tumor and design mRNA therapeutic sequences intended to help the immune system recognize and attack their unique cancer.
個人化癌症治療展示了其中一種方法的潛力:在開發過程中,研究人員辨識患者腫瘤中的突變,並設計 mRNA 治療序列,旨在協助免疫系統辨識並攻擊其獨特的癌症。
Each patient needs many different sequences, producing those sequences at scale with consistent quality and traceability for our customers who deliver those therapies to patients is directly in line with the challenges Twist was built to address. We already supply in templates and siRNA for selected customers, including DNA use in investigational therapies being evaluated in clinical trials. And in fiscal 2026, we excited complex genes and research greatly any preparation options to support the more demanding preclinical work, which is the underlying input for advanced MRN therapeutics.
每位患者都需要許多不同序列;以一致的品質與可追溯性為客戶進行規模化生產,讓客戶將這些療法交付給患者,正符合 Twist 建立之初要解決的挑戰。我們已為特定客戶供應模板與 siRNA,其中包括用於臨床試驗中評估之研究性療法的 DNA。在 2026 會計年度,我們擴充了複雜基因與研究級的多項製備選項,以支援要求更高的臨床前工作,而這些正是先進 mRNA 治療的基礎投入。
Supplying the materials for companies developing MRA therapeutics is a natural next step. Today, we offer research grade mRNA to selected customers through early access with a high throughput offering in development. For personalized cancer therapies to reach minus of patients, manufacturing must become faster, more efficient and more affordable. Our ambition is to bring the economics of our platform to this emerging market supplying the molecules manufacturing capabilities our customers need to scale.
為開發 mRNA 治療的公司供應材料,是順理成章的下一步。目前,我們透過早期存取(early access)向特定客戶提供研究級 mRNA,並正在開發高通量產品。若要讓個人化癌症療法惠及數百萬名患者,製造必須更快速、更有效率且更具成本效益。我們的目標是將平台的經濟性帶入這個新興市場,提供客戶擴大規模所需的分子與製造能力。
We are building this opportunity in stages. Early clinical programs generate modest revenue, but supporting customers now positions us to grow with them when their therapy is advanced just as we did in nucleic acid. This is a medium- to long-term opportunity. And we believe that we do not need the material contribution from nucleic acid therapeutics to deliver our growth in the coming years.
我們將分階段打造這項機會。早期臨床專案帶來的營收有限,但現在支援客戶可讓我們在其療法推進時與其共同成長,就如同我們在核酸領域所做的一樣。這是一個中長期機會。我們相信,在未來幾年實現成長的過程中,並不需要核酸治療帶來重大的營收貢獻。
On slide 8, NGS is delivering strong growth today. Fourth quarter revenue grew 24% year-over-year and 6% sequentially, driven by diagnostic customers. Two weeks ago, we launched MRD X risk commercially, and we are seeing strong interest in this unique and important product. We expect MRD Express to drive growth next year and beyond.
在第 8 張投影片,NGS 目前正帶來強勁成長。第四季營收年增 24%,季增 6%,主要由診斷客戶帶動。兩週前,我們正式商業化推出 MRD Xpress,我們看到市場對這項獨特且重要的產品有強烈興趣。我們預期 MRD Express 將在明年及更長期帶動成長。
To take a step back, minimal residual disease or MRD refers to traces of cancer that remain after treatment. Tumor-naive B test use shared cancer biomarker associated with the particular cancer and the same panel of biomarker will be used to monitor all people with the same type of cancer. We serve many customers that use our panels within their tumor naive assets. Where Twist further differentiates itself is in the supplying panels for tumor-informed test. Because tumor DNA varies from person to person, to more inform MRD assays use this unique tumor signatures to create a personalized panel that is then used to nip off all recurrence. As you can imagine, sensitivity is a key focus for our customers developing these tests.
退一步說,微小殘存病灶(minimal residual disease,MRD)是指治療後仍殘留的癌症痕跡。腫瘤非知情(tumor-naive)檢測使用與特定癌症相關的共通癌症生物標記,同一套生物標記面板可用於監測所有同類型癌症患者。我們服務許多客戶,他們在其腫瘤非知情檢測中使用我們的面板。Twist 進一步差異化之處在於供應用於腫瘤知情(tumor-informed)檢測的面板。由於腫瘤 DNA 因人而異,腫瘤知情 MRD 檢測會使用該患者獨特的腫瘤特徵建立個人化面板,並用於監測任何復發。如你所想,靈敏度是開發這些檢測的客戶關注的關鍵重點。
Recent studies demonstrated that test, including thousands of probes result in increased sensitivity, and we believe thousands of variance will be necessary to drive success in the broader market over time. It's a future in which our customers MRD testing reaches millions of assays each year, beating the demand requires individualized panels at a normal scale, building directly on our ability to mature millions of DNA sequences in parallel.
近期研究顯示,包含數千個探針的檢測可提升靈敏度;我們相信,隨著時間推進,為了在更廣泛市場取得成功,將需要數千個變異位點。未來情境是:客戶的 MRD 檢測每年可達數百萬次;要滿足這樣的需求,就需要以常態化規模提供個別化面板,而這正是建立在我們能並行製造數百萬條 DNA 序列的能力之上。
For this market, we are also building ahead of the demand we are seeing, providing security for customer supply chain as they scale. In relation to MRD, our sequencer-agnostic NGS portfolio spans different target enrichment, library preparation and other sequencing components. In fiscal 2026, we introduced labor preparation solutions for all genome sequencing applications, including rare disease and operational genetics. This product group is growing rapidly.
針對此市場,我們也在看到的需求之前提前建置產能,為客戶在擴大規模時的供應鏈提供保障。就 MRD 而言,我們的「與定序儀無關」(sequencer-agnostic)的 NGS 產品組合涵蓋不同的目標富集、文庫製備及其他定序組件。在 2026 會計年度,我們推出適用於所有全基因體定序應用的文庫製備解決方案,包括罕見疾病與族群遺傳學。此產品群正在快速成長。
Turning to slide 9. We raised approximately $425 million in net proceeds through an equity offering and at the market sales. This capital gives us flexibility to expand the discovery characterization capabilities prepared for MRD growth and act on emerging opportunities. Moving forward, we will apply the discipline that brought us to positive adjusted EBITDA and invest ahead of demand, improve efficiency and build capabilities that can generate attractive returns while remaining adjusted EBITDA positive. We have shown that we can build new capabilities and turn them into growth as we have with antibody characterization and data.
接著看第 9 張投影片。我們透過股權發行與市場內銷售(ATM)籌得約 4.25 億美元的淨收益。這筆資金讓我們能更有彈性地擴充發現與表徵能力,以因應 MRD 成長並把握新興機會。展望未來,我們將延續帶領我們達成調整後 EBITDA 轉正的紀律:在需求之前投資、提升效率,並建置可帶來具吸引力報酬的能力,同時維持調整後 EBITDA 為正。我們已證明能建立新能力並將其轉化為成長,就如同我們在抗體表徵與資料方面所做到的。
Next, Paddy will discuss how we are expanding capacity and improving the speed and efficiency of our workflows.
接下來,Paddy 將說明我們如何擴充產能,並提升工作流程的速度與效率。
Patrick Finn - President, Chief Operating Officer
Patrick Finn - President, Chief Operating Officer
Thanks, Emily, and good morning, everyone. Our customers want to test more sequences explore more complex molecules and move programs faster. Our job is to deliver the right molecule with the right quality on time and do it again at greater scale.
謝謝你,Emily,大家早安。我們的客戶希望測試更多序列、探索更複雜的分子,並更快推進專案。我們的工作是在正確的時間交付具備正確品質的正確分子,並以更大的規模重複做到這一點。
On slide 10, in fiscal 2026, we expanded capacity across datasets, protein solutions and NGS through automation and capital investment ahead of demand. We are connecting production steps and strengthening digital systems to process thousands of different footings and generate tens of thousands of data points every day.
在第 10 張投影片,於 2026 會計年度,我們透過自動化與資本投資,在需求到來之前就於資料集、蛋白解決方案與 NGS 領域擴充產能。我們正在串聯生產步驟並強化數位系統,以處理數千種不同的基礎構件,並每天產生數萬個資料點。
In fiscal 2026, we introduced approximately 30 automated systems and workflow, increasing throughput and speed across protein expression, antibody characterization, MRD and NGS. We bring capacity online in stages guided by customer demand to shorten the time from a customer's design to their next informed decision. We have capacity available to serve additional customers today we're investing now to support the larger more complex programs we see ahead.
在 2026 會計年度,我們導入約 30 套自動化系統與工作流程,使蛋白表達、抗體特性分析、MRD 與 NGS 的產出量與速度均提升。我們依客戶需求分階段上線產能,以縮短從客戶設計到其下一次做出有依據決策的時間。我們目前已有可用產能可服務更多客戶;同時我們現在就投資,以支援未來我們所看到更大、更複雜的專案。
Our strong balance sheet allows us to invest in CapEx to support multiple ins of opportunity across the business. And in many cases, this is an investment in specialized instruments. And while it's relatively easy to add equipment for automation, buying an instrument is only the beginning. The real work begins by designing the efficient processes, engineering the connections between machines and writing the software that makes the workflow operate reliably at scale. We have spent the last decade building our team that designed the processes connect the equipment and enable a proprietary software to allow operators working around the clock to operate sophisticated machines consistently, improving the efficiency and speed. We're always striving to increase speed, efficiency and economics, and our experience in automation engineering provides added differentiation from our peers.
我們強健的資產負債表使我們能投資資本支出(CapEx),以支援公司內多個機會領域。而在許多情況下,這些投資是用於專用儀器。雖然為自動化新增設備相對容易,但購買儀器只是開始。真正的工作在於設計高效率流程、工程化機器之間的連結,以及撰寫讓工作流程能在大規模下可靠運作的軟體。過去十年,我們建立了一支團隊,負責設計流程、連接設備,並開發專有軟體,使操作人員能 24 小時不間斷地一致操作精密機器,提升效率與速度。我們始終致力於提升速度、效率與經濟性,而我們在自動化工程方面的經驗,讓我們相較同業更具差異化優勢。
Today, we have 10 DNA writers operating with two installations planned in the months ahead and 4 more in order. With all 16 operating we will have capacity to manufacture more than 50 million pieces of DNA daily supporting AI drug discovery, nucleic acid therapeutics, MRB and other applications.
目前我們有 10 台 DNA 寫入器在運作,未來幾個月還計畫再安裝 2 台,另有 4 台已下單。當 16 台全部運作時,我們將具備每日製造超過 5,000 萬段 DNA 的產能,以支援 AI 藥物研發、核酸治療、MRB 及其他應用。
On slide 11, MRD Express puts that capacity to work. Each panel is designed around individual tumors variants with consistent requirements for quality, reproducibility and speed. This is precisely the challenge our platform was built to address. Across these markets, we're adding capacity ahead of demand and making existing capacity more productive. Customers gain faster delivery and the ability to bring us more of their workflow is gain opportunity to grow revenue and improve manufacturing efficiency. Delivering for customers today and building for the next challenge is how we earn repeat business and how we operate as a supply chain partner that can keep pace as programs drove volume and complexity.
在第 11 張投影片,MRD Express 讓這些產能發揮效益。每個 panel 都是圍繞個別腫瘤變異所設計,並對品質、可重現性與速度有一致的要求。這正是我們平台所打造來解決的挑戰。在這些市場中,我們在需求之前就增加產能,並讓既有產能更具生產力。客戶可獲得更快的交付,並能把更多工作流程交由我們處理;我們則獲得營收成長機會並提升製造效率。為今日的客戶交付成果、並為下一個挑戰建置能力,是我們贏得重複業務的方式,也是我們作為供應鏈合作夥伴、能在專案推動量能與複雜度提升時保持步調的運作方式。
With that, I'll turn the call over to Adam.
接下來我把電話交給 Adam。
Adam Laponis - Chief Financial Officer
Adam Laponis - Chief Financial Officer
Thank you, Paddy. On slide 12, we accelerated growth, exceeded fourth quarter revenue guidance and achieved positive adjusted EBITDA while investing in our sales team, capital equipment and software. Revenue for the fourth quarter was $126.6 million compared with $99 million in the fourth quarter of fiscal 2025, an increase of 28% year-over-year and 7% sequentially. For the full year, revenue was $459.4 million compared with $376.6 million in fiscal '25, growth of 22%.
謝謝你,Paddy。在第 12 張投影片,我們加速成長、第四季營收超越指引,並在投資銷售團隊、資本設備與軟體的同時,達成調整後 EBITDA 轉正。第四季營收為 1.266 億美元,較 2025 會計年度第四季的 9,900 萬美元增加 28%(年增),並較前一季增加 7%。全年營收為 4.594 億美元,較 2025 會計年度的 3.766 億美元成長 22%。
On slide 13, DNA synthesis and Protein Solutions revenue was $61 million in the fourth quarter, up $33 per year and 8% sequentially. Full year revenue was $221.9 million, up 32% and reflecting therapeutics growth and adoption of our broader DNA protein and characterization capabilities.
在第 13 張投影片,DNA 合成與蛋白解決方案第四季營收為 6,100 萬美元,年增 33%,季增 8%。全年營收為 2.219 億美元,成長 32%,反映治療領域成長,以及客戶採用我們更廣泛的 DNA、蛋白與特性分析能力。
We ship genes in the fourth quarter and approximately $1.3 million for the full year. We also manufacture genes used internally to produce proteins and characterization data. Year-over-year, annual gene ship volume grew 43%, while volume used internally more than doubled. Both categories support AI drug discovery and other applications generating revenue through gene sales, or the proteins data and discovery services we deliver.
我們在第四季出貨基因,全年約為 130 萬美元。我們也製造內部使用的基因,用於產生蛋白與特性分析資料。以年對年來看,年度基因出貨量成長 43%,而內部使用量增加逾一倍。這兩類皆支援 AI 藥物研發與其他應用,透過基因銷售,或我們交付的蛋白、資料與研發服務來創造營收。
On slide 14, NGS applications returned to growth above 20%, consistent with our guidance in February. Fourth quarter revenue was $65.7 million, up 24% year-over-year and 6% sequentially, driven by diagnostic customers. Full year revenue was $237.5 million, up 14%. Our top 10 NGS applications customers accounted for approximately 40% of NGS applications revenue in the quarter. We served over 700 NGS applications customers, including 190 customers adopting our products.
在第 14 張投影片,NGS 應用回到 20% 以上的成長,符合我們 2 月的指引。第四季營收為 6,570 萬美元,年增 24%、季增 6%,主要由診斷客戶帶動。全年營收為 2.375 億美元,成長 14%。本季我們前 10 大 NGS 應用客戶約占 NGS 應用營收的 40%。我們服務超過 700 家 NGS 應用客戶,其中包括 190 家採用我們產品的客戶。
On slide 15, looking at revenue by industry. Therapeutics revenue was $43.9 million in the quarter, up 44% year-over-year. Full year revenue grew by $51.8 million to $162.3 million, up 47%. This includes $59.1 million from AI drug discovery customers, an increase of $37.6 million or 175% over fiscal 2025. All of this revenue sits inside our therapeutics line with therapies growing well above the company average this year.
在第 15 張投影片,從產業別來看營收。治療領域第四季營收為 4,390 萬美元,年增 44%。全年營收增加 5,180 萬美元至 1.623 億美元,成長 47%。其中包括來自 AI 藥物研發客戶的 5,910 萬美元,較 2025 會計年度增加 3,760 萬美元,增幅 175%。上述營收皆計入我們的治療產品線;今年治療業務的成長遠高於公司平均。
Our imported AI revenue captures only what we can clearly categories is AI. We know that traditional drug discovery pharma and biotech customers are also adding AI programs alongside their traditional approaches. As we move forward, drawing a clear distinction will become much more difficult.
我們所揭露的 AI 營收僅涵蓋我們能明確歸類為 AI 的部分。我們知道,傳統藥物研發的製藥與生技客戶,也正在在其傳統方法之外加入 AI 專案。隨著我們持續向前,要做出清楚區分將變得更加困難。
Diagnostics revenue was $45.2 million in the quarter, growth of 23% and $154.3 million for the full year, growth of 13%. Academic and government revenue was $16.1 million in the quarter, an increase of 21%. For the year, revenue grew 13% to $56.6 million. Industry and applied revenue was $6.6 million in the quarter, growth of 12%. Full year revenue was $24.2 million. Global Supply Partner revenue was $15 million in the quarter, an increase of 18% and and $52 million for the year, growth of 13%.
診斷領域第四季營收為 4,520 萬美元,成長 23%;全年為 1.543 億美元,成長 13%。學術與政府領域第四季營收為 1,610 萬美元,增加 21%。全年營收成長 13% 至 5,660 萬美元。產業與應用領域第四季營收為 660 萬美元,成長 12%。全年營收為 2,420 萬美元。全球供應合作夥伴(Global Supply Partner)第四季營收為 1,500 萬美元,增加 18%;全年為 5,200 萬美元,成長 13%。
On slide 16, Geographically, Americas revenue was $78.8 million in the fourth quarter, an increase of 38% year-over-year. EMEA revenue was $38.7 million, growth of 12%, and APAC revenue was $9.2 million, a growth of 28%.
在第 16 張投影片,按地區來看,美洲第四季營收為 7,880 萬美元,年增 38%。EMEA 營收為 3,870 萬美元,成長 12%;APAC 營收為 920 萬美元,成長 28%。
Turning to slide 17. I Fourth quarter gross margin was 53.1% compared with 51.3% a year ago. Full year gross margin was 52.4% compared with 50.7% in fiscal 2025. The Operating expenses, excluding cost of revenue, were $91.7 million for the fourth quarter and $38.3 million for the full year. Our fiscal 2026 investments supported commercial execution digital infrastructure and expanded capabilities across the business.
接著看第 17 張投影片。第四季毛利率為 53.1%,高於一年前的 51.3%。全年毛利率為 52.4%,高於 2025 會計年度的 50.7%。營業費用(不含營收成本)第四季為 9,170 萬美元,全年為 3,830 萬美元。我們在 2026 會計年度的投資支援了商業執行、數位基礎設施,並擴展了全公司範圍的能力。
On slide 18, adjusted EBITDA was positive $2.2 million in the fourth quarter. For the year, adjusted EBITDA was a loss of $35.9 million. Capital expenditures were approximately $20 million, including tenant improvements in the fourth quarter and $48 million for the full year. As Paddy discussed, this spending supports expanded characterization capabilities, automation and additional DNA writers.
在第 18 張投影片中,第四季調整後 EBITDA 為正 220 萬美元。全年而言,調整後 EBITDA 為虧損 3,590 萬美元。資本支出約為 2,000 萬美元,其中包含第四季的承租人裝修(tenant improvements),全年合計為 4,800 萬美元。如 Paddy 所述,這些支出支持擴增的表徵(characterization)能力、自動化以及額外的 DNA 寫入器(DNA writers)。
Turning to slide 19. We ended fiscal 2026 with $582 million in cash, cash equivalents and short-term investments. This includes $424.8 million in aggregate net proceeds from our public offering and aftermarket program. Over fiscal 2027 and fiscal 2028, we expect approximately $150 million in capital expenditures for capacity, automation and software, plus more than $30 million in landlord-funded tenant improvements. We anticipate these planned investments will expand our long-term capacity to support more than $1 billion in annual revenue within our existing facilities at scale. We will face deployment ahead of the demand we see coming.
接著看第 19 張投影片。我們在 2026 會計年度結束時,現金、約當現金及短期投資為 5.82 億美元。其中包含我們公開發行與後續市場計畫(aftermarket program)合計淨募資 4.248 億美元。在 2027 與 2028 會計年度期間,我們預期資本支出約 1.5 億美元,用於產能、自動化與軟體,另加上超過 3,000 萬美元由房東出資的承租人裝修。我們預期這些規劃中的投資,將在既有設施規模化運作下,擴大我們的長期產能,以支援年營收超過 10 億美元。我們將在看到的需求之前先行部署產能。
Turning to slide 20. We entered fiscal 2027 with strong momentum across BSPS and NGS and clear visibility into our first quarter outlook. A drug discovery, oncology diagnostics, academic and government customers and new products give us multiple drivers of sustained growth.
接著看第 20 張投影片。我們以 BSPS 與 NGS 兩大業務的強勁動能進入 2027 會計年度,且對第一季展望具備清晰能見度。藥物發現、腫瘤診斷、學術與政府客戶以及新產品,為我們帶來多重持續成長的驅動力。
Our capacity and automation investments position us to capture demand and improve productivity as volume scales. The pace of margin expansion reflects depreciation and manufacturing costs as new capacity comes online before reaching planned utilization, partially offset by productivity improvements. These investments expand the revenue capacity of our existing facilities and improved productivity as volume growth.
我們在產能與自動化方面的投資,使我們能在量能擴大時掌握需求並提升生產力。毛利率擴張的速度反映了:在新產能上線、尚未達到規劃稼動率之前的折舊與製造成本;部分由生產力改善所抵銷。這些投資擴大了既有設施的營收承載能力,並在出貨量成長時提升生產力。
Over fiscal 2027, margin outlook includes the cost of bringing that capacity on -- the combination of commercial momentum, broader capabilities and disciplined investment supports our revenue growth outlook above 20% in fiscal 2020. Consistent with our historical approach, we have built our initial outlook around the demand and delivery timing. We have a high degree of confidence in converting to revenue during the year.
在 2027 會計年度,毛利率展望包含啟用該產能的成本——商業動能、更廣泛的能力與嚴謹的投資紀律,支持我們在 2020 會計年度營收成長高於 20% 的展望。一如我們過往的做法,我們的初始展望是以需求與交付時程為基礎建立。我們對於在年度內轉化為營收具有高度信心。
For fiscal 2027, we expect total revenue of $550 million to $560 million, representing growth of approximately 21% at the midpoint. Our initial full year revenue guidance assumes $100 million in AI drug discovery revenue. This reflects the customer programs, lead funnel and delivery schedules we can forecast with a high degree of confidence today. We see additional opportunities in expanding programs with both existing customers and new customer programs that are not fully reflected in our initial full year guidance.
針對 2027 會計年度,我們預期總營收為 5.50 億至 5.60 億美元,以中位數計約成長 21%。我們初始的全年營收指引假設 AI 藥物發現營收為 1 億美元。這反映了我們目前能以高度信心預測的客戶專案、潛在案源(lead funnel)與交付排程。我們也看到更多機會,包括擴大既有客戶的專案,以及新增客戶專案;這些尚未完全反映在我們初始的全年指引中。
We expect sequential growth in DNA synthesis and protein solutions and NGS applications throughout the year. Gross margin of approximately 52.5% to 53%, positive adjusted EBITDA for the full year. Capital expenditures of approximately $75 million as part of our two-year investment plan, excluding landlord-funded tenant improvements.
我們預期全年 DNA 合成與蛋白質解決方案,以及 NGS 應用將呈現逐季成長。毛利率約為 52.5% 至 53%,全年調整後 EBITDA 為正。資本支出約 7,500 萬美元,作為我們兩年投資計畫的一部分,不含房東出資的承租人裝修。
For the first quarter of fiscal 2027, we expect revenue of $130 million to $132 million, representing growth of approximately 26% year-over-year at the midpoint, and continued sequential growth for both ESPS and NGS, with each product group growing about 25% year-over-year.
針對 2027 會計年度第一季,我們預期營收為 1.30 億至 1.32 億美元,以中位數計年增約 26%,且 ESPS 與 NGS 皆將持續逐季成長;各產品組別年增約 25%。
With that, I'll turn the call back to Emily.
接下來我把電話交回給 Emily。
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
Thank you, Adam. On slide 21, we measure progress in revenue growth, gross margin and adjusted EBITDA. In fiscal 2026, we grew revenue 22%, expanded gross margin and delivered positive adjusted EBITDA in the fourth quarter. Moving forward, we are building on that strong foundation.
謝謝你,Adam。在第 21 張投影片,我們以營收成長、毛利率與調整後 EBITDA 來衡量進展。在 2026 會計年度,我們營收成長 22%,毛利率擴張,並在第四季交出正的調整後 EBITDA。展望未來,我們將在這個堅實基礎上持續推進。
At Twist, we make our own weather. We grew through COVID. We grew academic revenue when funding was under pressure. We expanded our biotech customer base with Capital West Care. Our diversity across products, markets and customers gives us resilience and multiple ways to grow.
在 Twist,我們能自己創造環境。我們在 COVID 期間仍持續成長。在資金承壓時,我們仍讓學術營收成長。
We believe health care is moving towards personalized diagnosis, treatment and monitoring. AI is accelerating what customers can design, turning those designs into millions of unique molecules with consistent quality is the next challenge. Twist was built to deliver customized solutions at scale. To provide an analogy, making spaghetti for two is easy. Now imagine 1 million people placing 1 million different orders. every dish has to be right. Every plate has to arrive on time, delivering that takes an entirely different system designed for customization from the start. That is the challenge we at Twist to solve in biology.
我們相信醫療保健正走向個人化的診斷、治療與監測。AI 正加速客戶能設計的內容;而將這些設計以一致品質轉化為數百萬種獨特分子,是下一個挑戰。Twist 的打造初衷,就是要以規模化方式交付客製化解決方案。打個比方,為兩個人煮義大利麵很容易。現在想像有 100 萬人下了 100 萬個不同的訂單。每一道菜都必須正確無誤。每一盤都必須準時送達;要做到這點,需要一套從一開始就為客製化而設計、完全不同的系統。這就是我們 Twist 要在生物領域解決的挑戰。
Our platform and automation make custom at scale possible. As health care becomes more personalized, the world will need millions of unique molecules met reliably and efficiently. We are building the infrastructure for that future.
我們的平台與自動化讓「以規模化方式客製」成為可能。隨著醫療保健愈加個人化,世界將需要數以百萬計的獨特分子,且必須可靠且高效率地被滿足。我們正在為那樣的未來打造基礎設施。
We bring start-up energy and enterprise discipline to everything we do. We move fast, stay close to customers and turn emerging needs into new capabilities. We hold ourselves accountable for the quality, reliability and scale our customers depend on. We build Twist for where biology is going. We have the platform the people and the capital to lead them. Now we intend to turn that advantage into sustained growth.
我們在所做的一切中,兼具新創的活力與企業級的紀律。我們行動迅速、貼近客戶,並將新興需求轉化為新能力。我們對客戶所依賴的品質、可靠性與規模負起責任。我們打造 Twist,是為了迎向生物學的發展方向。我們擁有平台、人才與資本來引領這一切。現在我們打算把這項優勢轉化為可持續的成長。
We are just getting started. Operator, please open the call for questions.
我們才剛剛開始。接線員,請開放提問。
Operator
Operator
(Operator Instructions)
(接線員指示)
Subbu Nambi, Guggenheim.
Guggenheim 的 Subbu Nambi。
Subbu Nambi - Equity Analyst
Subbu Nambi - Equity Analyst
Hey, guys. Good morning. Thank you for taking my question. AI revenue exceeded our initial expectation in 2026. You guided $200 million for 2027, which is the same number you've been talking about for a while. But now it's off of a higher base, I believe, approximately $60 million. With this in mind, I have a few questions.
嗨,各位。早安。謝謝讓我提問。AI 營收在 2026 年超出我們最初的預期。你們對 2027 年給出的指引是 2 億美元,這個數字你們談了一段時間。但我認為現在是建立在更高的基礎之上,大約 6,000 萬美元。基於此,我有幾個問題。
Yes, your revenue target is impressive, and it's still robust growth, but it's a moderation, especially given how you have described the market opportunity. Why would growth moderate? Do the error bars skew to the upside? How much of this is accounted for in backlog? And can you speak to the order growth?
是的,你們的營收目標令人印象深刻,成長仍然強勁,但成長速度有所放緩,尤其考量你們對市場機會的描述。為什麼成長會放緩?不確定性區間(error bars)是否偏向上行?其中有多少已反映在積壓訂單(backlog)中?另外能否談談訂單成長?
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
Thanks Subbu, for your question. Indeed, we see the growth accelerating for the business. In Q1, we had 17% revenue growth, 19% in Q2, 2 in Q3 and now 28% in Q4. So I think that's a business we're doing well. we are very confident in the potential for us to achieve triple-digit percentage order growth in fiscal 2027 for AI drug discovery.
謝謝你,Subbu,謝謝你的提問。確實,我們看到業務成長正在加速。第一季營收成長 17%,第二季 19%,第三季 2%,而第四季達到 28%。所以我認為我們的業務表現良好。我們對於在 2027 會計年度於 AI 藥物發現領域達成三位數百分比的訂單成長潛力非常有信心。
And also convert more orders into revenue within the year. And you're right that our initial guidance is for $100 million in the AI drug discovery revenue. And those are programs that we can forecast with high confidence today.
同時也能在年度內把更多訂單轉化為營收。你說得沒錯,我們的初始指引是 AI 藥物發現營收 1 億美元。這些是我們目前能以高度信心進行預測的專案。
And so we see that there is meaningful upside on top of that assumption. And really, there's 2 things for us to do. The first one is to add more capacity, that part of the business is growing really fast and and keeping ahead of the demand is key. So it's totally now in our control. And then the second is to add workflow in hydro discovery, same as in traditional drug discovery and not everybody wants to do the same thing.
因此我們看到,在這項假設之上仍有相當可觀的上行空間。而且,對我們來說真正有兩件事要做。第一是增加產能,這部分業務成長非常快,並且領先需求是關鍵。所以現在完全在我們的掌控之中。第二是在 hydro discovery(Hydro 探索)中加入工作流程,和傳統藥物探索一樣,而且並不是每個人都想做同樣的事情。
And so for instance, 2 weeks ago, we've added a cell-free workflow. And that's an example of an expanded workflow for us. We really like the sale free. It's a better margin for us. It's faster for customers.
例如,兩週前我們新增了一個無細胞(cell-free)工作流程。這就是我們擴展工作流程的一個例子。我們非常喜歡無細胞。對我們而言毛利更好。對客戶而言也更快。
And then we have a unique advantage we're the only ones to be able to do cell-free for longer protein such as ITG where others are limited to to mini vide and DHS. So overall, this is the guide that we have high confidence in today, but there's a lot of upside on top of it.
此外我們還有一個獨特優勢:我們是唯一能夠針對較長蛋白(例如 ITG)做無細胞的公司,而其他人則受限於 mini vide 和 DHS。總體而言,這就是我們今天非常有信心的指引,但在此之上仍有很大的上行空間。
Operator
Operator
Mac Etoch, Stephens.
Mac Etoch,Stephens。
Steven Etoch - Equity Analyst
Steven Etoch - Equity Analyst
Hey, good morning, and thank you for taking my questions. Maybe following up on Subbu's question, given the AI expectations or at least the AI print for FY26 and the expectations for '27, I think it would suggest that you're expecting roughly mid-single-digit growth in the underlying PSPS business. So can you just speak to the underlying characteristics of that market?
嗨,早安,謝謝讓我提問。或許延續 Subbu 的問題,考量 FY26 的 AI 預期、或至少 FY26 的 AI 表現,以及對 '27 年的預期,我認為這暗示你們預期底層 PSPS 業務大約是中個位數成長。能否談談該市場的底層特性?
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
Yes, yes. So I think the characteristic of the AI business that we are seeing is that -- first of all, it works, right? The quality of the planning that the quality of the developability that our customers' models are producing on par of what you can get with in vivo in vitro. And so the science is working.
是的,是的。我認為我們看到的 AI 業務特性是——首先,它是有效的,對吧?我們客戶模型所產出的規劃品質、以及可開發性(developability)的品質,與你在體內/體外(in vivo / in vitro)能得到的水準相當。所以科學是行得通的。
We are seeing that, yes, people come first with model building. which is great. But then they are converting to true drug discovery programs where they declare a target. And then they go through the disco process and move to preclinical development and come back with another target. And that business, that run rate business is very sustainable. It's bigger than the initial model building. And so it's -- we can see that it's a business for the long term.
我們也看到,沒錯,人們一開始會先做模型建構。這很好。但接著他們會轉換成真正的藥物探索專案,亦即他們會確立一個標的(target)。然後他們會走完整個探索流程,推進到臨床前開發,接著再帶著另一個標的回來。而那種業務——那種穩定的 run rate 業務——是非常可持續的。它比最初的模型建構更大。因此——我們可以看到這是一門長期的生意。
The other thing where the other charters that we are seeing is that people want more and more different ways of doing drug discovery. Even within one company, they may have started with Array drug discovery, where they're getting on sequence per tube and they get one data point per fits well. And there is still a lot of demand for that, but we are also seeing customers saying we need to grow the number of data points that we can study and the price per data point has to drop.
另外一點——我們看到的其他特性是,人們想要越來越多不同的藥物探索方式。即使在同一家公司內,他們可能一開始採用 Array 藥物探索,在那裡他們每個孔/每支管只放一個序列,並且每個孔只得到一個數據點。這方面仍然有很大的需求,但我們也看到客戶表示:我們需要提升可研究的數據點數量,而且每個數據點的價格必須下降。
And those customers, they are very much looking for ways to do what we call pooled discovery. So instead of having one sequence in one well, now you have thousands, hundreds of thousands, maybe millions of different sequences in one well, in one tube. And that's a really great match for us in how we make our DNA.
而這些客戶非常積極在尋找我們所稱的 pooled discovery(混合式探索)方法。也就是不再是一個孔裡一個序列,而是在同一個孔、同一支管裡有成千上萬、數十萬,甚至可能數百萬個不同序列。這與我們製作 DNA 的方式非常契合。
So we solved the making of the DNA and the protein. But then you have to characterize each of those and you have to go to full discovery. So we are seeing extension of the workflows in that direction. Then another characteristic and maybe I'll stop there. is we're also seeing that, of course, the AI native logic companies, they are moving at a very fast clip, but we are seeing more and more people getting into it.
因此我們解決了 DNA 和蛋白的製作。但接著你必須對其中每一個進行特性鑑定,並且必須走到完整的探索流程。所以我們看到工作流程正朝這個方向延伸。然後還有另一個特性——我可能先說到這裡。我們也看到,當然,AI 原生(AI-native)的邏輯公司推進速度非常快,但我們也看到越來越多人加入其中。
And so where maybe a year ago, it was just a few companies, and maybe there were some questions as to whether the science will work. I think now in companies that we are doing traditional drug discovery, we see more and more of excitement about AI. So definitely a great time for us to be in business. It's great that we are one of the leaders, and it's a perfect match for the platform that we have. And yes, we are very much looking for continued growth in this coming year.
因此,或許在一年前,只有少數幾家公司,而且可能還有人質疑科學是否可行。我認為現在,在我們所服務、從事傳統藥物探索的公司裡,我們看到對 AI 的興奮感越來越高。所以這絕對是我們經營業務的好時機。我們很高興自己是領導者之一,而且這與我們的平台完美契合。是的,我們非常期待在接下來一年持續成長。
Operator
Operator
(Operator Instructions)
(接線員指示)
Doug Schenkel, UBS.
Doug Schenkel,UBS。
Douglas Schenkel - Equity Analyst
Douglas Schenkel - Equity Analyst
Good morning, everyone. Thank you for taking my question. So you guided to around $100 million of revenue growth year-over-year in fiscal '27, around $40 million of this is attributed to AI, as you guided to, I think, about 67% growth there. What drives the other $60 million? How much is mRNA? How much is liquid biopsy? How much is biopharma excluding AI? And how much is traditional synbio?
各位早安。謝謝讓我提問。你們指引顯示在 27 財年年對年營收成長約 1 億美元,其中約 4,000 萬美元歸因於 AI,因為你們指引那部分大約成長 67%。其餘的 6,000 萬美元由什麼驅動?mRNA 佔多少?液體活檢佔多少?不含 AI 的生物製藥佔多少?以及傳統合成生物(synbio)佔多少?
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
Yes. Adam, do you want to take us through those numbers?
好的。Adam,你要不要帶我們走一遍這些數字?
Adam Laponis - Chief Financial Officer
Adam Laponis - Chief Financial Officer
No, absolutely, Doug. Great to hear you. Thank you for the question. When we look at the overall business year-over-year, excluding AI drug discovery, we're seeing the actual total growth of the business accelerate. We're really excited to see NGS be above 20% in Q4.
當然,Doug。很高興聽到你的聲音。謝謝你的問題。當我們看整體業務的年對年表現、並排除 AI 藥物探索後,我們看到業務的實際總成長正在加速。我們很興奮看到 NGS 在第四季超過 20%。
We guided that back in February and to be at 24% in Q4, it feels good. And we see that continued momentum in the business. We also recognize on the DSP side of the business, particularly in therapeutics. Many of our customers who are shifting towards AI drug discovery, and many of our reps are focusing on the hyper growth that's happening in AI drug discovery, that does have an impact on the pace of growth elsewhere, but we are forecasting to be still over double-digit growth for the rest of the business outside of AI drug discovery this year and actually seeing that growth accelerate year-on-year. So really excited to be there. And again, we'll continue to provide updates as the year continues.
我們在二月給出指引,而第四季達到 24%,感覺很好。而且我們看到這股動能在業務中持續。我們也注意到在業務的 DSP 端,特別是在治療領域。我們許多客戶正轉向 AI 藥物探索,而我們許多業務代表也把重心放在 AI 藥物探索正在發生的高速成長上,這確實會影響其他領域的成長速度;但我們預測今年在 AI 藥物探索以外的其餘業務仍將維持兩位數以上成長,並且看到該成長年對年加速。所以我們對此非常興奮。同樣地,隨著年度進行,我們會持續提供更新。
Operator
Operator
Vijay Kumar, Evercore.
Vijay Kumar,Evercore。
Vijay Kumar - Equity Analyst
Vijay Kumar - Equity Analyst
Hi, Emily. Good morning, and thank you for taking the question. I guess one on this AI topic back on the 3Q call, you noted you continue to expect triple-digit order growth in fiscal '27 as well. And I think Adam made a comment about it's going to become increasingly difficult because traditional pharma customers are ordering and it's going to be hard to delineate AI revenues from traditional pharma.
嗨,Emily。早安,謝謝讓我提問。我想問一個關於 AI 的問題:在第三季電話會議上,你們提到也仍預期 27 財年訂單將維持三位數成長。我記得 Adam 也評論說,因為傳統藥廠客戶也在下單,未來會變得越來越困難,因為很難把 AI 營收與傳統藥廠區分開來。
So one, are you still expecting triple-digit AI order growth in fiscal '27 in the comment on that Adam made, are you -- will you be disclosing AI numbers going forward? And sorry, the last one you mentioned source of upside. If you could just elaborate on them.
所以第一,你們是否仍預期 27 財年 AI 訂單會有三位數成長?針對 Adam 的那段評論,你們——未來還會持續揭露 AI 的數字嗎?另外不好意思,最後一個:你們提到上行空間的來源。能否再多加說明?
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
Yes, we are committed to sharing AI revenue where we want to be as transparent as we can with our investors without keeping our competition too much. So that's the fine line we are doing. And as I mentioned, yes, it's getting harder for us to know when there is a previously traditional drug scrip group whether they switch to AI or not. I think in all of us, in all of our lives, we're using AI more and more and more, and the boundary becomes blurred, but what we do is report a hydro discovery for groups that we are sure that doing AI. And maybe it's a little bit undercounted. But that's what we'll do.
是的,我們致力於分享 AI 收入;在不讓競爭對手掌握太多資訊的前提下,我們希望對投資人盡可能透明。因此我們一直在拿捏這條微妙的界線。而且如我先前提到的,是的,對我們而言,越來越難判斷某個原本傳統的藥物處方群組是否已經轉向使用 AI。我想在我們所有人、在我們的日常生活中,我們使用 AI 的頻率愈來愈高,界線也變得模糊;但我們的作法是:對於我們確信正在使用 AI 的群組,我們就回報一項「hydro discovery」。而這可能會有些低估。但我們會這麼做。
In terms of upside, right, there's there's a lot of levers for us to push, right? There's the level of first finding more customers. Another level lever is launch more workflows to capture more wallet share of customers. The cell-free launch is one example of that a couple of weeks ago.
就上行空間而言,對吧,我們有很多槓桿可以推動,對吧?其中一個層面是先找到更多客戶。另一個槓桿是推出更多工作流程,以提高在客戶端的錢包占比。幾週前推出的無細胞(cell-free)產品就是其中一個例子。
And see, when we launched the MRD Express, that's the opportunity to push of the fans, customers that maybe would want to do the MRD our way with thousands of growth. But within 5 days for bespoke panel, well, 5 days is actually quite amazing to ship thousands of probes for thousands of customers that one. Actually, we've heard from customers that actually 5 days that was too long.
你看,當我們推出 MRD Express 時,那就是一個推動的機會,去吸引那些可能想用我們的方式做 MRD、而且規模可達數千成長的客戶。但對於客製化 panel 而言,5 天——其實在 5 天內就能出貨數千個探針給數千位客戶,這真的相當驚人。不過我們也聽到客戶回饋,實際上 5 天還是太久了。
And so that's why we rose to the challenge and developed a process that could in 24 hours. So that's another lever for us. And then we probably have a few more surprises along the way. that again, we don't want to keep our competitors, but our NPI engine is really productive. And now that we've turned adjusted EBITDA breakeven, we'll be able to reinvest our product. And so I mean we're going to become even more of a dental standard.
所以這就是為什麼我們迎接挑戰,開發出可在 24 小時內完成的流程。這也是我們的另一個槓桿。此外,我們一路上可能還會有一些驚喜。同樣地,我們不想讓競爭對手掌握太多,但我們的 NPI 引擎確實非常高產。而且現在我們已經達到調整後 EBITDA 損益兩平,我們將能夠再投資於產品。所以我的意思是,我們會變得更像是一個「牙科標準」(dental standard)。
Operator
Operator
Puneet Souda, Leerink.
Puneet Souda,Leerink。
Puneet Souda - Analyst
Puneet Souda - Analyst
Yeah, hi, Emily and team. Thanks for taking my question. Look, you have a number of growth drivers. But clearly, one that's come up front is AI and obviously, a big part of the conversation just given the -- what that intelligence can actually do for drug discovery and the world. So I mean I'm hearing from you that you have significant demand coming, that's very clear. You're building CapEx, you're building -- you're getting writers, you're building lab automation quickly. But look, you just did 175% growth in AI revenues, you are projecting somewhere just shy of 70% growth for FY27 in revenue for AI, but your order growth, the triple-digit order growth.
是的,嗨,Emily 和團隊。謝謝你們回答我的問題。你們有多項成長驅動因素。但顯然,最被放到前面的其中一項是 AI;而且考量到那種智慧對藥物發現以及整個世界能做的事情,這也很自然成為討論的重點。所以我的意思是,我從你們這裡聽到的是,你們有非常明確、顯著的需求正在到來。你們在擴建資本支出(CapEx),你們在建置——你們在增加合成產能(writers),你們在快速建置實驗室自動化。但你們剛剛在 AI 收入上做到 175% 的成長,你們預估到 FY27 AI 收入成長接近 70%,但你們的訂單成長是三位數的訂單成長。
I hear you, you are again validating that. But I'm just trying to understand, is there some dynamic here in terms of revenue versus order timing? Is there anything that we need to keep in mind with respect to the conversion of those revenues that -- from orders to revenues that's giving you sort of the 70% -- nearly 70% growth versus the triple-digit growth in revenue itself? And maybe just last part of it, if I could. What does triple-digit growth in orders mean? Is that somewhere like really north of 100%? Is this 200%? Is there kind of -- can you put a sort of number to it, I appreciate it. I appreciate the comments here.
我聽到了,你們也再次確認了這點。但我想理解的是:在收入與訂單時點之間,是否存在某種動態?在訂單轉換為收入的過程中,有沒有什麼我們需要留意的地方,導致你們給出的成長指引是約 70%——接近 70%——而不是像訂單那樣的三位數成長?另外最後一部分,如果可以的話。三位數的訂單成長代表什麼?是大概遠高於 100% 嗎?是 200% 嗎?你能不能給一個大概的數字,我會很感謝。也謝謝你們在這裡的說明。
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
Yes, thank you, Puneet. There is no dynamic between orders and revenue, and that's why we try to clean up and give the revenue number for both '25 and '26 to make it very clear. And so by triple-digit percent growth, we mean triple-digit person growth. So last year, we had 175%, right? Yes, this year, what we can take to the bank today, guarantee is $100 million.
是的,謝謝你,Puneet。訂單與收入之間沒有任何動態差異;這也是為什麼我們嘗試把資訊整理清楚,並提供 '25 與 '26 兩年的收入數字,讓它非常明確。所謂三位數百分比成長,我們指的就是三位數百分比成長。所以去年我們是 175%,對吧?是的,而今年我們今天可以拍胸脯、可以保證的是 1 億美元。
And we also see a lot of upside. Some of that upside if we want to realize it, we need to have the capacity -- to add the capacity. And so that's right, it's in our hands. And so we remain confident that we will be able to deliver triple-digit percentage growth in orders and revenue for fiscl '27. But today, the forecast with high confidence today is $100 million with more to come.
我們也看到很大的上行空間。其中一部分上行若要實現,我們需要有產能——需要增加產能。所以沒錯,這掌握在我們手上。因此我們仍然有信心,在 27 財年能夠在訂單與收入上都交付三位數百分比成長。但以今天的高信心預測來看是 1 億美元,而且後面還會有更多。
As you know, as for many years, we've now had had $15 million -- 15 consecutive quarters of revenue growth. And we strive to absolutely crush every quarter -- and here, we think that we are set up for that.
如你所知,多年來我們已經連續 15 個季度實現營收成長——每季增加 1,500 萬美元。我們力求每一季都要徹底超越預期——而在這裡,我們認為我們已經具備這樣的條件。
Operator
Operator
Matt Larew, William Blair.
Matt Larew,William Blair。
Matt Larew - Analyst
Matt Larew - Analyst
Good morning, everyone. I wanted to ask on the planned investments for capacity. Obviously, a big step up over the next couple of years. Just help us understand what the mix of sort of expanded scale of existing capabilities versus the CapEx that's dedicated to new capabilities.
各位早安。我想問一下關於產能的規劃投資。顯然,未來幾年會大幅提升。請幫我們理解一下:在既有能力的擴大規模,與用於新能力的資本支出(CapEx)之間,大概各占多少比重?
And given that you're making kind of this scale of investments right now, it might be helpful to understand kind of how the breadth of ordering is on a, I guess, what I mean is how many companies you're able to classify as truly making AI orders this year versus last versus the order funnel now, again, to kind of get a sense of what you're seeing that supports your decision to make all these investments.
另外,鑑於你們現在正在進行這種規模的投資,或許也有助於理解訂單來源的廣度;我的意思是,今年相較去年,你們能夠歸類為真正下 AI 訂單的公司有多少?以及目前的訂單漏斗又是什麼情況?同樣是為了更好地掌握你們看到的哪些訊號,支持你們做出這些投資決策。
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
Paddy, do you want to take that one?
Paddy,你要回答這題嗎?
Patrick Finn - President, Chief Operating Officer
Patrick Finn - President, Chief Operating Officer
Yes, I've got that. Thanks for the question. Good to hear you. I mean if we start at the top, I think I said in the comments that adding the fundamental righter capacity -- it's a great place to start. And we're going from something in the order of 32 million all of nucleotides or building blocks per day to go north of 50 million ologuclutides every single day, which is absolutely credible capacity.
是的,我來回答。謝謝你的問題。很高興聽到你的聲音。如果我們從最上游開始,我想我在評論中提到,增加基礎的合成產能(righter capacity)——這是一個很好的起點。我們將從每天約 3,200 萬個核苷酸或構建單元(building blocks)的量,提升到每天超過 5,000 萬個寡核苷酸(oligonucleotides),這是完全可信的產能。
And when you move downstream from DNA synthesis platform, I think what we showed on slide 10 was really balanced and disciplined deployment of capital. customer growth in the applications continues to go up in the way that we understand the market and the knowledge we have of our customers. And we're making sure that we're ahead of that demand.
當你從 DNA 合成平台往下游走,我認為我們在第 10 張投影片展示的是非常均衡且有紀律的資本部署。依照我們對市場的理解,以及我們對客戶的認識與掌握,應用端的客戶成長仍在持續上升。而我們要確保我們的供給走在需求之前。
And things like MRD Express in tumor informed panels, thousands of individual probes a panel for each patient and is really going to absorb a lot of that capacity that we're building. And that's for the development of new tests and also for customers who are ramping up with commercial efforts today, an antibody or the AI drug discovery opportunity. What we can see there is we're meeting our customers where they're at.
像 MRD Express 這類腫瘤知情(tumor informed)panel,每位病患的每個 panel 都有數千個單一探針,確實會吸收我們正在建置的大量產能。這既用於新檢測的開發,也用於那些目前正透過商業化努力加速放量的客戶——無論是抗體,或是 AI 藥物發現的機會。我們在那裡看到的是:我們正在在客戶所處的位置與他們對接。
We'll deliver DNA protein data, whatever it is, we need but we're really starting to understand what that demand is over time. And so in driving into that opportunity, we're adding capacity to deliver multiple thousands of proteins and antibodies every day and then obviously multiples of that number of data points per day. And as we understand and the customer demand and needs, we're obviously investing to get ahead of that. That's where we stand right now.
我們會交付 DNA 蛋白質資料,不管那是什麼;我們需要它,但我們也正逐步真正理解這項需求隨時間的樣貌。因此,為了把握那個機會,我們正在擴增產能,每天可交付數千種蛋白與抗體,當然每天也能產出其倍數的資料點。隨著我們更了解客戶需求與需要,我們顯然也在投資以領先布局。這就是我們目前的狀況。
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
Yes. And to be on what I said, that capacity has been coming, right? We've been deploying it. We've been talking about capacity, and that's why we did the fundraising in the summer. So the plan, the trends are on track.
是的。而且延續我剛才說的,那些產能一直在到位,對吧?我們一直在部署。我們也一直在談產能,這也是為什麼我們在夏天進行募資。所以整體計畫與趨勢都在軌道上。
Operator
Operator
Matt Stanton, Jefferies.
Matt Stanton,Jefferies。
Matthew Stanton - Analyst
Matthew Stanton - Analyst
Maybe on MRD, how should we think about the ability for that to accelerate here into 2027, I think it added a point or two in '26, you have new programs launching next-gen assays new products with MRD Express as we think about the ability for MRD to accelerate here into '27. And then any finer point in terms of what the guide contemplates for a contribution from MRD either for NGS or overall in '27?
關於 MRD,你認為我們應該如何看待它在 2027 年加速的能力?我想它在 2026 年貢獻了 1 到 2 個百分點;你們有新計畫在推進、下一代檢測(assays)與搭配 MRD Express 的新產品推出。當我們思考 MRD 在 2027 年加速的能力時,應該怎麼看?另外,在指引(guide)中,對於 2027 年 MRD 的貢獻(不論是對 NGS 或整體)是否有更細的說法?
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
Adam, would you mind taking that one?
Adam,你介意回答這題嗎?
Adam Laponis - Chief Financial Officer
Adam Laponis - Chief Financial Officer
Absolutely. So Matt, thank you for the question. When you look at what we did in 2026, we talked about -- we guided to 1 to 2 points of growth from MRD. We definitely delivered on those expectations, but we're seeing significant growth from MRD in terms of percent growth. But it's really early days in that commercial adoption.
當然。Matt,謝謝你的問題。回顧我們在 2026 年做的事情,我們曾提到——我們指引 MRD 將帶來 1 到 2 個百分點的成長。我們確實達成了那些預期,而且就成長百分比而言,我們看到 MRD 顯著成長。但在商業化採用方面,現在仍是非常早期的階段。
So it's a bit of a lot of small numbers of the growth rate in 2025 to 2026. We don't expect the growth rate as a percentage to slow. So the dollar growth continues to expand more rapidly as we go into '27, for MRD. And we see that potential, not just for '27, but '28 and beyond.
所以從 2025 到 2026 的成長率,有一部分是因為基期數字較小。我們不預期以百分比計的成長率會放緩。因此,隨著進入 2027 年,MRD 的美元成長會持續更快速地擴大。我們也看到這個潛力不只在 2027 年,還包括 2028 年及之後。
And as Paddy mentioned, some of the investments we're making today and things like new writers, things take 12 to 18 months to install and build out. So we're building not just for the capacity of 2027, but looking out into the future.
而且如 Paddy 提到的,我們今天正在做的一些投資,例如新的寫入設備(writers),安裝與建置需要 12 到 18 個月。所以我們不只是為了 2027 年的產能在建置,也是在放眼更長期的未來。
Operator
Operator
David Westenberg, Piper Sandler.
David Westenberg,Piper Sandler。
David Westenberg - Analyst
David Westenberg - Analyst
All right. Thanks for taking the question and congrats on the good quarter here. So DNA synthesis and protein solutions grew at 33%, while gene shipped grew even faster. Can you talk about how that was reflected in mix in terms of AI customers versus traditional customers, protein versus jeans here? And how should we think about pricing over the next few years here. And I'm going to be a bad loan slip in a second one.
好的。謝謝讓我提問,也恭喜本季表現不錯。DNA 合成與蛋白解決方案成長 33%,而基因出貨量成長更快。你們能談談這在組合(mix)上如何反映:AI 客戶相較於傳統客戶、以及蛋白相較於基因(jeans)?另外,未來幾年定價應該怎麼看?我接著還要再加問第二題。
But on the AI revenue characterization, can you give us just a few details about how you're categorizing it? Is it like the project they're telling you about? Are they like specifically telling you it's AI? I just want to get a little bit more color on how you're going to characterize it on a go-forward basis because you said it is difficult. Anyway, sorry, if you answered that, and that went over my head.
另外關於 AI 營收的定義/歸類,你們能否提供一些細節,說明你們是怎麼分類的?是依據客戶告訴你們的專案內容嗎?他們會明確告訴你們這是 AI 嗎?我想更了解你們未來會如何持續做這個分類,因為你們說過這很困難。總之抱歉,如果你們已經回答過而我漏聽了。
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
Yes. Thanks for the simple question. The volume of genes is going is growing. We love it. It's just growing very, very fast. And you're right that the gene volume is growing faster than the revenue. And that is because we price the base. And there's broadly two big categories of genes, one of genes that anchored for protein. Those are big average 1,500 basis engines and anchor for antibodies. And those are small, about 600 to 800 basis.
是的。謝謝這個簡單的問題。基因的量正在成長。我們很喜歡。它成長得非常、非常快。而你說得對,基因出貨量的成長快於營收成長。這是因為我們是按鹼基(base)定價。大致上有兩大類基因:一類是用於蛋白的基因。這類平均大約 1,500 個鹼基,並用於抗體。另一類則較短,大約 600 到 800 個鹼基。
And since we price per base while both categories are growing, the category for human antibody is just growing way faster on. So there is a mix shift that it just reflects that we're doing well on protein, and we are doing really well on antibodies. As far as characterization of the revenue, maybe to reiterate -- if it's an AI company, if it's a native AI does core company, that's easy is the purchase data is easy to put in the AI bucket. But I'm sure that there are customers that buy DNA from us or IgG from us that are derived from AI and we don't know. And we don't really care. We care about the revenue growth, the gross margin and the profitability.
由於我們按鹼基定價,雖然兩個類別都在成長,但人類抗體那一類的成長速度快得多。因此確實出現了組合轉移(mix shift),這反映出我們在蛋白表現良好,而在抗體方面表現非常好。至於營收的歸類方式,再重申一次——如果是 AI 公司、如果是原生 AI(native AI)或以 AI 為核心的公司,那很容易,因為採購資料很容易歸到 AI 這一桶。但我確信也有一些客戶向我們購買 DNA 或 IgG,而其實是由 AI 驅動/衍生的,只是我們不知道。而我們也不太在意。我們在意的是營收成長、毛利率與獲利能力。
Operator
Operator
Kyle Mikson, Canaccord Genuity.
Kyle Mikson,Canaccord Genuity。
Kyle Mikson - Equity Analyst
Kyle Mikson - Equity Analyst
Yeah. Hey, guys. Thanks for the questions. Congrats on the progress. If we assume you double revenue by 2031, fiscal '31, if you said at the Investor Day. And then you kind of grow the core low doubles, low teens, I guess, it kind of implies AI revenue of only $200 million by fiscal '31. So you kind of raised the question of how long this AI revenue tail left? How are you thinking about that the capacity and the demand on pharma and Frontier as did the risk that these entities start their own AI lab work as well?
是的,嗨,各位。謝謝讓我提問。恭喜你們的進展。如果我們假設你們在 2031 年(會計年度 '31)營收翻倍,正如你們在投資人日所說;而核心業務大概以低雙位數、低十幾%的速度成長,我想這會暗示到會計年度 '31 時 AI 營收只有約 2 億美元。所以這就引出一個問題:這條 AI 營收的長尾還能延續多久?你們如何看待產能與需求(在藥廠與 Frontier 端),以及這些機構自行建立 AI 實驗室/實驗作業的風險?
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
We think it's long lasting. Just the science work, right? And the science is broad-based. If you look back at cell and gene therapies, maybe everybody was working on one target. In this case, it's just broad-based.
我們認為這會是長期且持久的。就是科學研究工作本身,對吧?而且科學的應用面很廣。如果回頭看細胞與基因療法,可能大家都在做同一個標的。但在這裡,它是更廣泛、多面向的。
So we think it's going to last. And yes, maybe some customers will build their own lab that's define with us. They're going to need protein. They're going to need DNA. And they'll all roads have to go through with, so that's -- we don't see that as a problem. That's a feature of the Twist approach is we provide available menu and we'll meet our customers where they are.
所以我們認為它會持續。而且是的,也許有些客戶會建立自己的實驗室,與我們形成競合。但他們仍然需要蛋白。他們仍然需要 DNA。所有路徑終究都得經過我們,所以——我們不認為那會是問題。Twist 的方法的一個特點是:我們提供可用的產品選單,並在客戶所在的位置與他們對接。
Operator
Operator
Luke Sergott, Barclays.
Luke Sergott,Barclays。
Luke Sergott - Analyst
Luke Sergott - Analyst
Great. Thanks for the question. I want to ask one on the AI and then I want to touch on mRNA. So on the AI side, you're doing the buildout, you talked about having a little bit of upside there from your $100 million in orders and revenue. Is that contingent on capacity coming on in the back half?
很好。謝謝讓我提問。我想先問一題 AI,然後再談 mRNA。在 AI 方面,你們正在擴建,你們提到在 1 億美元的訂單與營收之上可能還有一些上行空間。那是否取決於下半年產能到位?
And then on the mRNA side, you guys talked about this being a bigger opportunity to you guys than the potential size of the AI piece, can you just kind of give us a quick -- where you fit within that workflow, how you're fitting now? Like where that's going, what the revenues are now and like what's embedded in?
然後在 mRNA 方面,你們談到這對你們而言是比 AI 潛在規模更大的機會;你們能否簡要說明——你們在整個工作流程(workflow)中扮演的位置、目前如何切入?未來會往哪裡走、目前的營收是多少,以及指引中包含了哪些內容?
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
Yes. Very little is embedded in '27. Right now, we are servicing the clinical trials that are ongoing. And so you can look like it's not a lot of patients. And the opportunity for us is once those trials are completed and then medicine is being delivered personally to millions of people. That's when we'll -- someone will have to make the G&A so that we want that to be us. someone will have to convert it into RNA.
是的。嵌入在「27」裡的內容非常少。目前,我們正在為正在進行的臨床試驗提供服務。因此你可能會覺得病患數量不多。而對我們而言的機會在於,一旦那些試驗完成,接著藥物會以個人化方式交付給數以百萬計的人。那時候我們就會——總得有人去做 G&A,所以我們希望那個人是我們。總得有人把它轉換成 RNA。
And that may be us, so that may be the customers we are open to all options. And so it's a longer-term opportunity for us. But that's what we do with Twist is we plant a seed now for the future. And then on AI, yes, capacity is being added every week. So we have a very active program. It's a well-oiled machine. And as we add capacity, we unleash our sales team to go sell it.
而那也可能是我們,因此那些可能就是客戶;我們對所有選項都持開放態度。所以這對我們而言是較長期的機會。但這就是我們與 Twist 合作時所做的事:現在先種下一顆種子,為未來做準備。至於 AI,是的,我們每週都在增加產能。所以我們有一個非常積極的計畫。這是一部運轉良好的機器。而當我們增加產能時,我們就會讓銷售團隊全力去把它賣出去。
Operator
Operator
Robert Bamberger, Baird.
Robert Bamberger,Baird。
Robert Bamberger - Analyst
Robert Bamberger - Analyst
Yeah, thanks for taking my question. Just on gross margins at the midpoint, fiscal 2027 adds about $96 million of revenue and $52 million of gross profit, so a 55% incremental gross profit conversion there. How do we bridge that to the 75% to 80% underlying contribution framework you've discussed in the past? And then with that investment program running through fiscal 2028, will it take until fiscal 2029 for reported incrementals to get back towards that level? Or can they recover sooner than that?
是的,謝謝讓我提問。就毛利率而言,在中位數情境下,2027 會增加約 9,600 萬美元營收與 5,200 萬美元毛利,因此增量毛利轉換率約 55%。我們要如何把這個數字銜接到你們過去談到的 75% 到 80% 的底層貢獻框架?另外,若這個投資計畫會一路持續到 2028 會計年度,是否要到 2029 會計年度,已揭露的增量才會回到接近那個水準?還是可以更早恢復?
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
Adam?
Adam?
Adam Laponis - Chief Financial Officer
Adam Laponis - Chief Financial Officer
No, happy to take the question. So we've talked a lot about the 75% to 80% drop-through, and that doesn't change. And we've achieved that benchmark since opening the fact of the future in Portland, and that still holds across both DSPS and NGS as we look.
沒問題,很樂意回答這個問題。我們談過很多次 75% 到 80% 的落底(drop-through),而這點沒有改變。自從在波特蘭啟用「未來工廠」以來,我們就達成了這個基準;而當我們檢視 DSPS 與 NGS 兩個業務時,這點仍然成立。
In 2027, as I mentioned in the call, we expect to invest about $75 million in CapEx with a capacity expansion and automation ahead of the demand. That represents approximately $15 million per year of depreciation on that or about 2 to 3 points of gross margin headwind, which we expect to offset the drop through revenue in 2027. We do expect to continue to see gross margin expansion in '27, just not at the same pace as we've seen in prior years.
在 2027 年,如同我在電話會議中提到的,我們預期將投資約 7,500 萬美元的資本支出(CapEx),在需求到來之前先進行產能擴張與自動化。這相當於每年約 1,500 萬美元的折舊,或約 2 到 3 個百分點的毛利率逆風;我們預期在 2027 年以營收的落底效應來抵消。我們確實預期在 27 年仍會看到毛利率擴張,只是不會像前幾年那樣快。
And so as the business matures, we continue to see a path to 60% gross margin in the future. That said, we're really managing the business to maximize the gross profit dollars of the business. We talk about making sure we'd rather run a $2 billion business at a 50% gross margin and a $1 billion business at a 60% gross margin. So as we move forward, the commitment to remain adjusted EBITDA positive and not go backwards on gross margins there. But really, we're focused on making sure we optimize the revenue growth in the gross profit dollars.
因此,隨著業務成熟,我們仍看到未來達到 60% 毛利率的路徑。話雖如此,我們真正管理業務的方式,是要把公司的毛利金額最大化。我們常說,我們寧可經營一家 20 億美元、毛利率 50% 的公司,也不要經營一家 10 億美元、毛利率 60% 的公司。所以往前看,我們承諾維持調整後 EBITDA 為正,且毛利率不倒退。但我們的重點其實是確保在毛利金額面,能把營收成長最佳化。
Operator
Operator
Brendan Smith, TD Cowen.
Brendan Smith,TD Cowen。
Brendan Smith - Analyst
Brendan Smith - Analyst
Great. Apologies for the audio lapse earlier guys. I want to ask one more on DSS. And I apologies if I missed it, but are you able to actually confirm how many customers fall into that AI data orders bucket at this point and really what the mix of that base is specifically?
很好。各位,抱歉剛才音訊中斷。我想再問一個關於 DSS 的問題。也抱歉如果我漏聽了,但你們目前能否確認,落在 AI 資料訂單那個類別的客戶數量到底有多少?以及那個客戶基礎的組成(mix)具體是什麼?
I'm really trying to understand if that's exclusively kind of a couple, I needed biotech in the front tier lab or if you're actually seeing kind of in real-time expansion of that customer bucket in a material way, and I guess within your assumptions for next year, how many customers do you expect to be kind of placing those AI orders at the course of '27 and really trying to unpack like how much of the growth next year is coming from existing customers placing more data orders versus like biotech and pharma customers now placing those increasingly to and adding to that bucket. So just any color on the growth breakdown would be great.
我主要想了解,這是否完全只是少數幾家、我需要的那種前段班實驗室的生技公司;或者你們是否真的在即時看到那個客戶類別以具體且顯著的方式擴張。並且我想問,在你們對明年的假設中,你們預期在 27 年期間大概會有多少客戶會下這類 AI 訂單?我也想拆解一下,明年的成長有多少是來自既有客戶下更多資料訂單, versus 生技與藥廠客戶現在也越來越多地下這些訂單、並加入那個客戶類別。所以若能提供一些成長拆解的補充說明會很有幫助。
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
Adam?
Adam?
Adam Laponis - Chief Financial Officer
Adam Laponis - Chief Financial Officer
Yes. No, happy to. So Brendan, what we're seeing is every -- as Emily mentioned on the call, every one of those cohorts as we move over the last 18 months and expansion into the number of customers engaging in AI drug discovery. It started off. Some of it was in big pharma, some of it was in native AI discovery.
是的,沒問題,很樂意。所以 Brendan,我們看到的是——如同 Emily 在電話會議中提到的——在過去 18 個月裡,隨著我們推進,每一個客群(cohort)都有擴張,參與 AI 藥物研發的客戶數量也在增加。一開始是這樣。其中一部分來自大型藥廠,一部分來自原生 AI 研發公司。
And then it's moved on and progressed. We've added even some of the Magnus 7 and some of the larger hyperscalers to the mix. But the mix predominantly relies on customers that, a, we've had in the past and who are focused on drug discovery, not just the comp.
接著它持續推進並發展。我們甚至把「Magnus 7」中的一些公司,以及一些更大型的超大規模雲端業者(hyperscalers)也納入組合。但整體組合主要仍仰賴於:a,我們過去就有的客戶;且這些客戶聚焦在藥物研發,而不只是 comp。
So we see that customer group expanding over time. We've seen it expand sequentially almost every quarter since we started and we are -- as we look forward, we expect that to expand. We talked last year about being dozens of customers -- so there is some degree of concentration, but we see that continuing to diffuse as the more and more folks are turning to AI drug discovery as part of their workflows.
因此我們看到這個客戶群會隨時間擴大。自從我們開始以來,幾乎每一季都看到它逐季擴張;而展望未來,我們預期它還會繼續擴張。我們去年談到大概是數十家客戶——所以確實存在一定程度的集中度,但我們看到隨著越來越多人把 AI 藥物研發納入其工作流程,這種集中度會持續被稀釋、分散。
Operator
Operator
Thank you. This concludes the question-and-answer session. I'll now turn it back to Emily Laproust, CEO and Cofounder, for closing remarks.
謝謝。問答環節到此結束。接下來我將把時間交回給執行長暨共同創辦人 Emily Laproust,請她做結語。
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
Thank you. We have a history of turning ambitious goals into results, and this year was another proof point. Our ambition for Twist keep growing and so does our ability to deliver. Thank you.
謝謝。我們一向能把雄心勃勃的目標轉化為成果,而今年又是另一個佐證。我們對 Twist 的企圖心持續成長,而我們的交付能力也同樣持續提升。謝謝。
Operator
Operator
Thank you for your participation in today's conference. This concludes the program. You may now disconnect.
感謝各位參與今天的會議。本次議程到此結束。您現在可以斷線。